Eli Lilly and Company 10-Qquarter ended 2026-03-31

Executive Summary

Eli Lilly’s Q1 2026 revenue rose 56% Y/Y as surging Mounjaro and Zepbound volumes more than offset lower realized prices. Earnings grew faster than sales, helped by a smaller acquired research and development charge and a lower tax rate, while operating cash flow remained below net income and manufacturing investment consumed a substantial share of cash generation. Lilly is expanding capacity and advancing an oral obesity medicine, but its growth is increasingly concentrated in incretins: Mounjaro and Zepbound supplied 65% of quarterly revenue. For investors, the opportunity is sustained demand and broader access; the principal test is whether volume growth continues to outweigh pricing pressure, launch costs and capacity demands.

Key Financial Highlights

• Growth mix: Mounjaro generated $8.66B, +125% Y/Y, and Zepbound $4.16B, +80%; cardiometabolic products contributed $15.8B, or ≈80% of revenue. Revenue growth reflected 65% higher volume, offset by a 13% price decline, with a 4% favorable foreign-exchange impact. Mounjaro’s $4.43B outside-U.S. revenue underscores the expanding international contribution.
• Earnings quality: OCF was $2.06B below net income; the supplied summaries do not isolate the cause of that gap. Acquired research and development expense fell to $584M from $1.57B, and the effective tax rate declined to 16.4% from 20.2%; neither benefit should be mistaken for recurring volume growth. Mounjaro and Zepbound also benefited from favorable one-time rebate and discount estimate adjustments.
• Capital allocation: Repurchases of $2.36B retired 2.4M shares, but shares outstanding fell only 1.3M net, from 944.8M to 943.5M. Lilly also paid $1.55B in dividends; stock-based compensation was $161M. Cash uses included capacity investment and the Ventyx acquisition.

Business Developments

Lilly’s stated strategy is to expand manufacturing and fund launches and pipeline development against expected demand. The immediate commercial engine remains injectable incretins, but the April 2026 U.S. approval of oral obesity medicine Foundayo (orforglipron) offers another route to growth. Lilly also reported positive Phase 3 endpoints for orforglipron in type 2 diabetes and retatrutide in type 2 diabetes; approvals, supply and uptake will determine whether these programs broaden the franchise.

Lilly acquired Ventyx Biosciences for $1.1B net of acquired cash, adding an oral inflammatory-disease program and $977M of preliminary acquired research and development assets. Pending acquisition agreements could require up to ≈$12B at closing, increasing potential demands on liquidity alongside manufacturing expansion. Outside the core incretin products, Jardiance collaboration revenue included a $250M one-time benefit; investors should separate that contribution from recurring product demand.

Risk Assessment

• Incretin concentration and pricing: Mounjaro and Zepbound supplied 65% of revenue, making results sensitive to coverage, competition and price concessions; a 13% price decline already offset part of Q1’s volume gain.
• Access and government policy: U.S. pricing agreements, negotiations with payers and pharmacy benefit managers, international pricing changes and government-set prices for selected products could constrain revenue even as treatment access expands.
• Manufacturing and product safety: Capacity expansion must keep pace with demand without quality interruptions, recalls or approval delays; product-liability claims involving Mounjaro and Zepbound could also raise costs.
• Investment and funding: Higher expected capital expenditures and up to ≈$12B of potential acquisition closing payments would compete with dividends and repurchases for cash, although Lilly reported $10.1B of unused committed bank credit.
• Litigation and tax: Continuing product, pricing and 340B litigation creates potential period-specific charges; unresolved U.S. tax examinations and intercompany-pricing proceedings leave outcomes uncertain.
• Foreign exchange: International growth increases sensitivity to currency movements; non-designated forward contracts generated $97M of Q1 income, illustrating that hedging results can affect reported earnings.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: FY2025 10-K.

Strategic Outlook and Investor Actionables

Lilly enters the next period with exceptional demand, a growing international Mounjaro business and an additional obesity launch. The investment case depends less on whether the franchise can grow than on whether access, realized prices and cash generation can keep pace with the scale of its expansion.

• Incretin economics: Track Mounjaro and Zepbound volume, realized-price trends and gross margin; sustained volume growth without further margin erosion would strengthen the thesis.
• Launch and supply: Track Foundayo uptake and manufacturing execution; shortages, quality setbacks or weak access would limit the benefit of pipeline progress.
• Cash discipline: Compare OCF with net income and capital expenditures, and watch net share-count reduction against repurchase spending—particularly if pending acquisitions close.